The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse
Open accessAbstract
DNA methylation of CpG islands around gene transcription start sites results in gene silencing and plays a role in leukemia pathophysiology. Its impact in leukemia progression is not fully understood. We performed genomewide screening for methylated CpG islands and identified 8 genes frequently methylated in leukemia cell lines and in patients with acute myeloid leukemia (AML): NOR1, CDH13, p15, NPM2, OLIG2, PGR, HIN1, and SLC26A4. We assessed the methylation status of these genes and of the repetitive element LINE-1 in 30 patients with AML, both at diagnosis and relapse. Abnormal methylation was found in 23% to 83% of patients at diagnosis and in 47% to 93% at relapse, with CDH13 being the most frequently methylated. We observed concordance in methylation of several genes, confirming the presence of a hypermethylator pathway in AML. DNA methylation levels increased at relapse in 25 of 30 (83%) patients with AML. These changes represent much larger epigenetic dysregulation, since methylation microarray analysis of 9008 autosomal genes in 4 patients showed hypermethylation ranging from 5.9% to 13.6% (median 8.3%) genes at diagnosis and 8.0% to 15.2% (median 10.6%) genes in relapse (P < .001). Our data suggest that DNA methylation is involved in AML progression and provide a rationale for the use of epigenetic agents in remission maintenance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia
Agrawal, S., Hofmann, W.-K., Tidow, N., Ehrich, M., Boom, D. V. D., Koschmieder, S., Berdel, W. E., Serve, H., & Müller-Tidow, C. (2007) · Blood · doi:10.1182/blood-2006-08-040147 · Cited by 119
Cited by
Dnmt3a is essential for hematopoietic stem cell differentiation
Challen, G. A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J. S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., et al. (2012) · Nature Genetics · doi:10.1038/ng.1009 · Cited by 1,122
Self-citationMolecular biomarkers in acute myeloid leukemia
Prada-Arismendy, J., Arroyave, J. C., & Röthlisberger, S. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.08.005 · Cited by 304
Digging deep into “dirty” drugs – modulation of the methylation machinery
Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84
“…of all analyzed genes) are frequently hypermethylated in MDS, and that hypermethylation across the genome correlates with poor prognosis and transformation to AML, as well as AML relapse (Figueroa et al., 2009; Jiang et al., 2009; Kroeger et al., 2008; Maegawa et al., 2014; Zhao et al., 2014).”
Background
Metadata
- Authors
- Kroeger, H., Jelinek, J., Estécio, M. R. H., He, R., Kondo, K., Chung, W., Zhang, L., Shen, L., Kantarjian, H. M., Bueso-Ramos, C. E., & Issa, J.-P. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-08-15
- Volume
- 112
- Issue
- 4
- Pages
- 1366-1373
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1970224079
- Cited by
- 159
- References
- 1
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. https://app.cochat.ai/papers/10.1182/blood-2007-11-126227
- The paper
- Kroeger, H., Jelinek, J., Estécio, M. R. H., He, R., Kondo, K., Chung, W., Zhang, L., Shen, L., Kantarjian, H. M., Bueso-Ramos, C. E., & Issa, J.-P. J. (2008). Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. https://doi.org/10.1182/blood-2007-11-126227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.